USPTO 2015–2025 USPTO PatentsView US Corporation

Seven Bridges Genomics Inc.

USPTO PatentsView assignee record - 65 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G16B (Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology).

RSS updates for this company

The verdict

According to USPTO PatentsView, Seven ranks #5,320 of 49,997 tracked US assignees by granted-patent volume, with 65 patents across 11 technology areas.

#5,320
of 49,997 US assignees by volume
Top 31%
by Innovation Score (42.2/100)
18.6
avg claims per patent
+95%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5320 · US Corporation #5,320 · 65 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 65 grants
  • UPPER-Q #5,320/49,997
  • PHOTO-FINISH Schneider Toshiba…
  • CPC-FOCUS G16B · 11 areas
  • INNOV-PAR 42.2/100
  • CLAIMS-RICH 18.6 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +95% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Schneider Toshiba Inverter Europe SAS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Seven

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Seven's Innovation Score is 42.2/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Seven's grants concentrate

Seven Bridges Genomics Inc. is a focused PatentsView assignee: 11 CPC subclasses with 92.3% of grants classified under G16B (Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology). Peak complete grant year is 2020 (13 grants) versus a trough of 1 in 2016. By volume, Seven sits between SDS Asia Limited, BVI #1748971 and Subsea 7 Limited.

Seven's three-year grant acceleration

From 2019–2021 to 2022–2024, Seven Bridges Genomics Inc. moved from 29 to 21 grants (0.72x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Who files at Seven's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Seven holds 65 patents at rank #5,320, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Seven

By rank, the assignees closest to #5,320 in granted patent volume.

Leaders in G16B (Bioinformatics)

Other assignees with the most granted patents in Seven's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Seven, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Similar claim depth

Nearest assignees by average claims per patent (18.6 here).

Seven's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

051015 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Seven Bridges Genomics Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 3 4.6%
2016 1 1.5%
2017 2 3.1%
2018 6 9.2%
2019 9 13.8%
2020 13 20.0%
2021 7 10.8%
2022 8 12.3%
2023 8 12.3%
2024 5 7.7%
2025partial year 3 4.6%

Where it ranks

Overall rank by patents

#5,320

of 49,997 tracked assignees

Innovation Score

42.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Seven Bridges Genomics Inc.'s patent record in context - here's where to go next.

  • Seven Bridges Genomics Inc.'s lead technology class is G16B (Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology), 92.3% of its portfolio - see every assignee active in that class. Explore G16B
  • Ranked #5,320 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Seven Bridges Genomics Inc. against SDS Asia Limited, BVI #1748971, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 42.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.